16 results on '"Al-Jehani R"'
Search Results
2. Erratum: Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-α and the transcriptional repressor PLZF
- Author
-
Buluwela, L, Pike, J, Mazhar, D, Kamalati, T, Hart, S M, Al-Jehani, R, Yahaya, H, Patel, N, Sarwarl, N, Heathcote, D A, Schwickerath, O, Phoenix, F, Hill, R, Aboagye, E, Shousha, S, Waxman, J, Lemoine, N R, Zelent, A, Coombes, R C, and Ali, S
- Published
- 2005
- Full Text
- View/download PDF
3. P91 EFFECT OF TOLL-LIKE RECEPTOR 7 AND 9 TARGETED THERAPY TO PREVENT THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA
- Author
-
Mohamed, F., primary, Al-Jehani, R., additional, Minogue, S., additional, Andreola, F., additional, Winstanley, A., additional, Olde Damink, S., additional, Malagó, M., additional, Davies, N., additional, Loung, T.V., additional, Dhillon, A., additional, Mookerjee, R., additional, Dhar, D., additional, and Jalan, R., additional
- Published
- 2014
- Full Text
- View/download PDF
4. Characterisation of marker chromosomes in testicular tumours by banding, RFLP analysis, & fluorescence in situ hybridisation
- Author
-
Parrington, J.M., primary, Al Jehani, R., additional, Wells, D., additional, and Fox, M., additional
- Published
- 1992
- Full Text
- View/download PDF
5. Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-aand the transcriptional repressor PLZF.
- Author
-
Buluwela, L., Pike, J., Mazhar, D., Kamalati, T., Hart, S. M., Al-Jehani, R., Yahaya, H., Patel, N., Sarwarl, N., Heathcote, D. A., Schwickerath, O., Phoenix, F., Hill, R., Aboagye, E., Shousha, S., Waxman, J., Lemoine, N. R., Zelent, A., Coombes, R. C., and Ali, S.
- Subjects
ESTROGEN ,BREAST cancer ,HORMONE receptors ,LEUKEMIA ,PROTEINS ,PROGESTERONE receptors - Abstract
Estrogen receptora(ERa) is a ligand-inducible transcription factor that acts to regulate gene expression by binding to palindromic DNA sequence, known as the estrogen response element, in promoters of estrogen-regulated genes. In breast cancer ERaplays a central role, where estrogen-regulated gene expression leads to tumor initiation, growth and survival. As an approach to silencing estrogen-regulated genes, we have studied the activities of a fusion protein between ERaand the promyelocytic leukemia zinc-finger (PLZF) protein, a transcriptional repressor that acts through chromatin remodeling. To do this, we have developed lines from the estrogen-responsive MCF-7 breast cancer cell line in which the expression of the fusion protein PLZF-ERais conditionally regulated by tetracycline and shows that these feature long-term silencing of the expression of several well-characterized estrogen-regulated genes, namely pS2, cathepsin-D and the progesterone receptor. However, the estrogen-regulated growth of these cells is not inhibited unless PLZF-ERaexpression is induced, an observation that we have confirmed both in vitro and in vivo. Taken together, these results show that PLZF-ERais a potent repressor of estrogen-regulated gene expression and could be useful in distinguishing estrogen-regulated genes required for the growth of breast cancer cells.Gene Therapy (2005) 12, 452-460. doi:10.1038/sj.gt.3302421 Published online 13 January 2005 [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
6. Correlation of Loss of Heterozygosity with Cytogenetic Analysis Using G-banding and Fluorescence In Situ Hybridization in Aneuploid Cultures from Two Human Testicular Germ-Cell Tumors
- Author
-
Al-Jehani, R. M. A., Wells, D., Fox, M., and Parrington, J. M.
- Published
- 1995
- Full Text
- View/download PDF
7. Model for the molecular genetic diagnosis of endometrial cancer using K-ras mutation analysis.
- Author
-
Al-Jehani, R M, Jeyarajah, A R, Hagen, B, Hogdall, E V, Oram, D H, and Jacobs, I J
- Published
- 1998
- Full Text
- View/download PDF
8. Further cytogenetic analysis of two testicular tumour cell lines with fluorescence in situ hybridisation (FISH) using chromosome specific paint probes, YACs and cosmids
- Author
-
Wells, D., Taylor, C., Al-Jehani, R., Fox, M., and Parrington, J.M.
- Published
- 1994
- Full Text
- View/download PDF
9. p53 codon 72 polymorphism and risk of cervical cancer in UK.
- Author
-
Rosenthal, Adam N., Ryan, Andy, Al-Jehani, Rajai M., Storey, Alan, Harwood, Catherine A., Jacobs, Ian J., Rosenthal, A N, Ryan, A, Al-Jehani, R M, Storey, A, Harwood, C A, and Jacobs, I J
- Subjects
- *
CERVICAL cancer , *PAPILLOMAVIRUSES , *TUMOR suppressor genes , *GENETIC polymorphisms , *GENETICS - Abstract
Background: A polymorphism at codon 72 of the human tumour-suppressor gene, p53, results in translation to either arginine or proline. A recent report suggested that the risk of human-papillomavirus-associated cervical cancer in white women is higher for those homozygous for the arginine allele than for those who are heterozygous. We examined a similar number of cervical cancers and a larger control group for their p53 codon 72 polymorphism status to see if we could confirm this result.Methods: Three different groups of UK white women were studied: 96 who had volunteered to take part in a trial of ovarian-cancer screening; 150 attending for routine antenatal care in the Oxford region; and 50 women with cervical cancer. DNA from peripheral blood samples and from archival tissue samples was examined by PCR with allele-specific primers.Findings: The proportions of individuals homozygous for the arginine allele, homozygous for the proline allele, and heterozygous for the two alleles were 59%, 4%, and 36% among women screened for ovarian cancer; 65%, 8%, and 27% among the antenatal-care group; and 54%, 6%, and 40% in women with cervical cancer. Chi2 analysis showed no significant differences in these proportions.Interpretation: In the population studied, individuals homozygous for the arginine variant of codon 72 of the p53 gene were not at increased risk of cervical cancer. [ABSTRACT FROM AUTHOR]- Published
- 1998
- Full Text
- View/download PDF
10. Activation of the P38-MSK1 axis in colorectal adenocarcinoma determines a good prognostic outcome.
- Author
-
F Gayyed M, Monir Soliman M, Fouad Ahmed M, Mohamed Hassanin T, Munir Al Jehani R, and Zahraa Ammar Mohamed FE
- Subjects
- Humans, Immunohistochemistry, Prognosis, Ribosomal Protein S6 Kinases, 90-kDa, Adenocarcinoma, Colorectal Neoplasms
- Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide and is associated with a high level of mortality and morbidity. In this study we evaluate expression of p-p38 and p-MSK1 in CRC and determine whether there is an association between expression of these markers and any clinicopathologic parameters that could be of prognostic value. Expression of p-p38, p-MSK1 and ki-67 were examined by immunohistochemistry in 135 archival CRC cases and the findings were correlated with the patient clinicopathological data. P-p38 and p-MSK1 were expressed at high level in 58.5 % and 60.7% of CRC cases respectively. A statistically significant negative correlation was found between expression of p-p38 and Ki-67 (p < 0.001, r = -0.63) and between p-MSK1 and Ki-67 expression (p < 0.001, r = -0.61). The majority of CRC cases expressing high levels of p-p38 also expressed high levels of p-MSK1 and this correlation was highly significant (p < 0.001, r = 0.863). The high expression of p-p38 and p-MSK1 was also significantly associated with low Dukes and TNM stage. The elevated expression of p-38 and p-MSK1 in CRC was associated with a good prognosis and prolonged overall survival (p < 0.001, each). Our finding showed that activation of the p38-MSK1 axis determines a good outcome in CRC.
- Published
- 2021
- Full Text
- View/download PDF
11. Expression of TLR-2 in hepatocellular carcinoma is associated with tumour proliferation, angiogenesis and Caspase-3 expression.
- Author
-
Mohamed FEA, Hammad S, Luong TV, Dewidar B, Al-Jehani R, Davies N, Dooley S, and Jalan R
- Subjects
- Adult, Carcinoma, Hepatocellular metabolism, Caspase 3 metabolism, Cell Proliferation physiology, Female, Humans, Liver Neoplasms metabolism, Male, Middle Aged, Neovascularization, Pathologic metabolism, Neovascularization, Pathologic pathology, Biomarkers, Tumor metabolism, Carcinoma, Hepatocellular pathology, Liver Neoplasms pathology, Toll-Like Receptor 2 metabolism
- Abstract
Aims: Unlike other Toll-like receptors (TLRs), the role of toll like receptor 2 (TLR-2) in the pathogenesis of chronic liver disease and hepatocellular carcinoma (HCC) is not well studied. We, therefore, set out to investigate the expression of TLR-2 in different chronic liver disease states along with other markers of cell death, cellular proliferation and tissue vascularisation METHODS AND RESULTS: Immunohistochemistry was performed on liver tissue microarrays comprising hepatitis, cirrhosis and HCC patient samples using antibodies against TLR-2, Ki-67, Caspase-3 and VEGF. This was done in order to characterise receptor expression and translocation, apoptosis, cell proliferation and vascularisation. Cytoplasmic TLR-2 expression was found to be weak in 5/8 normal liver cases, 10/19 hepatitis cases and 8/21 cirrhosis patients. Moderate to strong TLR-2 expression was observed in some cases of hepatitis and cirrhosis. Both, nuclear and cytoplasmic TLR-2 expression was present in HCC with weak intensity in 11/41 cases, and moderate to strong staining in 19/41 cases. Eleven HCC cases were TLR-2 negative. Surprisingly, both cytoplasmic and nuclear TLR-2 expression in HCC were found to significantly correlate with proliferative index (r = 0.24 and 0.37), Caspase-3 expression (r = 0.27 and 0.38) and vascularisation (r = 0.56 and 0.23). Further, nuclear TLR-2 localisation was predominant in HCC, whereas cytoplasmic expression was more prevalent in hepatitis and cirrhosis. Functionally, treatment of HUH7 HCC cells with a TLR-2 agonist induced the expression of cellular proliferation and vascularisation markers CD34 and VEGF., Conclusions: Our results demonstrate a positive correlation between the expression of TLR-2 and other markers of proliferation and vascularisation in HCC which suggests a possible role for TLR-2 in HCC pathogenesis., (Copyright © 2020 Elsevier GmbH. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
12. T:G mismatch-specific thymine-DNA glycosylase (TDG) as a coregulator of transcription interacts with SRC1 family members through a novel tyrosine repeat motif.
- Author
-
Lucey MJ, Chen D, Lopez-Garcia J, Hart SM, Phoenix F, Al-Jehani R, Alao JP, White R, Kindle KB, Losson R, Chambon P, Parker MG, Schär P, Heery DM, Buluwela L, and Ali S
- Subjects
- Amino Acid Motifs, Amino Acid Sequence, Animals, COS Cells, Chlorocebus aethiops, Histone Acetyltransferases, Humans, Molecular Sequence Data, Nuclear Receptor Coactivator 1, Repetitive Sequences, Amino Acid, Trans-Activators chemistry, Transcription Factors chemistry, Tyrosine analysis, Thymine DNA Glycosylase chemistry, Thymine DNA Glycosylase metabolism, Trans-Activators metabolism, Transcription Factors metabolism
- Abstract
Gene activation involves protein complexes with diverse enzymatic activities, some of which are involved in chromatin modification. We have shown previously that the base excision repair enzyme thymine DNA glycosylase (TDG) acts as a potent coactivator for estrogen receptor-alpha. To further understand how TDG acts in this context, we studied its interaction with known coactivators of nuclear receptors. We find that TDG interacts in vitro and in vivo with the p160 coactivator SRC1, with the interaction being mediated by a previously undescribed motif encoding four equally spaced tyrosine residues in TDG, each tyrosine being separated by three amino acids. This is found to interact with two motifs in SRC1 also containing tyrosine residues separated by three amino acids. Site-directed mutagenesis shows that the tyrosines encoded in these motifs are critical for the interaction. The related p160 protein TIF2 does not interact with TDG and has the altered sequence, F-X-X-X-Y, at the equivalent positions relative to SRC1. Substitution of the phenylalanines to tyrosines is sufficient to bring about interaction of TIF2 with TDG. These findings highlight a new protein-protein interaction motif based on Y-X-X-X-Y and provide new insight into the interaction of diverse proteins in coactivator complexes.
- Published
- 2005
- Full Text
- View/download PDF
13. Silencing of androgen-regulated genes using a fusion of AR with the PLZF transcriptional repressor.
- Author
-
Pike J, Holmes D, Kamalati T, Davies D, Tolhurst R, Mazhar D, Fishpool S, al-Jehani R, Waxman J, Zelent A, Lemoine NR, Ali S, and Buluwela L
- Subjects
- Animals, Base Sequence, COS Cells, DNA Primers, Fluorescent Antibody Technique, Indirect, Genes, Reporter, Humans, Kruppel-Like Transcription Factors, Promyelocytic Leukemia Zinc Finger Protein, Recombinant Fusion Proteins genetics, Androgens physiology, DNA-Binding Proteins genetics, Gene Expression Regulation physiology, Gene Silencing, Receptors, Androgen genetics, Recombinant Fusion Proteins physiology, Transcription Factors genetics
- Abstract
The androgen receptor (AR) is a member of the nuclear receptor superfamily of ligand-activated transcription factors and plays a key role in the development and progression of prostate cancer. Current therapies include the use of antiandrogens aimed at inhibiting the transcriptional activation of AR-regulated genes by AR. Here, we explore a strategy aimed at obtaining silencing of AR-regulated genes, based on the properties of the transcriptional repressor promyelocytic leukamia zinc-finger protein (PLZF). In order to do this, we have made a fusion protein between PLZF and AR, named PLZF-AR, and show that PLZF-AR is able to bring about silencing of genomically encoded AR-regulated genes and inhibit the androgen-regulated growth of LNCaP prostate cancer cells. Together, our results show that this strategy is able to bring about potent repression of AR-regulated responses and, therefore, could be of value in the development of new therapies for prostate cancer.
- Published
- 2004
- Full Text
- View/download PDF
14. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10.
- Author
-
Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, Isaacson PG, and Dogan A
- Subjects
- Adaptor Proteins, Signal Transducing, Adult, Aged, Aged, 80 and over, Antigens, CD analysis, Biopsy, Carrier Proteins analysis, Cell Separation methods, Clone Cells metabolism, Clone Cells pathology, Cytoskeletal Proteins, DNA, Viral analysis, DNA-Binding Proteins analysis, Epstein-Barr Virus Infections metabolism, Epstein-Barr Virus Infections pathology, Female, Gene Rearrangement, B-Lymphocyte, Heavy Chain, Gene Rearrangement, T-Lymphocyte, Herpesvirus 4, Human isolation & purification, Humans, Immunoblastic Lymphadenopathy metabolism, Immunoblastic Lymphadenopathy virology, Immunoenzyme Techniques, In Situ Hybridization, Intracellular Signaling Peptides and Proteins, Ki-67 Antigen analysis, LIM Domain Proteins, Lymph Nodes chemistry, Lymph Nodes pathology, Lymphoma, T-Cell metabolism, Lymphoma, T-Cell, Peripheral classification, Lymphoma, T-Cell, Peripheral metabolism, Lymphoma, T-Cell, Peripheral pathology, Male, Micromanipulation, Middle Aged, Polymerase Chain Reaction, Proto-Oncogene Proteins analysis, Proto-Oncogene Proteins c-bcl-6, Pseudolymphoma metabolism, Pseudolymphoma pathology, Transcription Factors analysis, Biomarkers, Tumor analysis, Immunoblastic Lymphadenopathy pathology, Lymphoma, T-Cell pathology, Neoplasm Proteins analysis, Neoplastic Stem Cells metabolism, Neprilysin analysis, T-Lymphocytes metabolism
- Abstract
Angioimmunoblastic T-cell lymphoma (AITL) is a systemic disease involving lymph nodes, spleen, and bone marrow. Although the histologic features have been well described, the diagnosis is often challenging, as there are no specific phenotypic or molecular markers available. This study shows that the neoplastic cells of AITL can be identified by aberrant CD10 expression. Archival material from 30 cases of AITL, 10 cases of peripheral T-cell lymphoma unspecified (PTL), and 10 cases of reactive lymphoid hyperplasia were reviewed. Single and double immunostaining for CD3, CD4, CD8, CD20, CD21, CD10, BCL6, Ki67, and LMP-1 in situ hybridization for Epstein-Barr early region and polymerase chain reaction (PCR) for T-cell receptor gamma chain gene and immunoglobulin heavy chain gene were performed. Three overlapping histologic patterns with hyperplastic follicles, depleted follicles, or without follicles were identified in AITL. Of the 30 cases of AITL, 27 contained CD10(+) T cells. No CD10(+) T cells were present in the cases of PTL or reactive hyperplasia. PCR confirmed a monoclonal or oligoclonal T-cell population in 29 of 30 cases of AITL and a monoclonal B-cell population in 6 cases. Analysis of microdissected CD10(+) single cells showed that they belonged to the neoplastic clone. In conclusion CD10 is a phenotypic marker that specifically identifies the tumor cells in 90% of AITL, including the early cases. The presence of these cells distinguishes AITL from other PTLs. This finding provides an objective criterion for accurate and early diagnosis of AITL.
- Published
- 2002
- Full Text
- View/download PDF
15. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.
- Author
-
Ryan A, Al-Jehani RM, Mulligan KT, and Jacobs IJ
- Subjects
- Alleles, Base Sequence, Biomarkers, Tumor genetics, Cell Cycle physiology, Chromosomes, Human, Pair 9, DNA Primers analysis, DNA Primers chemistry, DNA Primers genetics, DNA, Neoplasm analysis, DNA, Neoplasm chemistry, DNA, Neoplasm genetics, DNA, Satellite analysis, DNA, Satellite chemistry, DNA, Satellite genetics, Female, Gene Expression Regulation, Neoplastic genetics, Gene Expression Regulation, Neoplastic physiology, Genes, p16 physiology, Humans, Loss of Heterozygosity, Microsatellite Repeats, Mutation, Ovarian Neoplasms physiopathology, Polymerase Chain Reaction methods, DNA Methylation, Genes, p16 genetics, Ovarian Neoplasms genetics
- Abstract
The p16ink4/CDKN2/MTS1 tumor suppressor gene encodes a cyclin-dependent kinase inhibitor which plays an important role in regulation of the G1/S phase cell cycle checkpoint. Loss of heterozygosity (LOH) at the p16 locus, 9p21, has been documented in a wide variety of tumors including ovarian carcinoma. However, inactivating mutations of the remaining allele and homozygous deletions are relatively infrequent events in primary tumors, even in cases where expression of p16 at the mRNA and protein level is clearly absent. These findings initially cast doubt on the role of p16 as a tumor suppressor gene in vivo. Recently, an alternative mechanism of p16 inactivation involving methylation of the CpG island in the 5' region of the gene has been demonstrated in a number of malignancies and cell lines. In this study we have analyzed the methylation status of four CpG dinucleotides in a panel of 23 ovarian tumors using a multiplex PCR approach to correlate our findings with the LOH data in this region. Using the microsatellite markers D9S171 and D9S1679 LOH was demonstrated in 4/22 (18%) informative cases. All 23 tumors showed no evidence of methylation at the p16 locus including the 4 tumors demonstrating LOH at 9p21. These results suggest that methylation inactivation of the p16 gene does not play an important role in ovarian carcinogenesis., (Copyright 1998 Academic Press.)
- Published
- 1998
- Full Text
- View/download PDF
16. Loss of heterozygosity on chromosome arms 5q, 11p, 11q, 13q, and 16p in human testicular germ cell tumors.
- Author
-
al-Jehani RM, Povey S, Delhanty JD, and Parrington JM
- Subjects
- Adult, Chromosome Mapping, Chromosomes, Human, Pair 11 genetics, Chromosomes, Human, Pair 13 genetics, Chromosomes, Human, Pair 16 genetics, Chromosomes, Human, Pair 5 genetics, Humans, Male, Middle Aged, Alleles, Chromosome Deletion, Chromosomes, Human genetics, Neoplasms, Germ Cell and Embryonal genetics, Testicular Neoplasms genetics
- Abstract
To identify common regions of deletion in human testicular germ cell tumors (TGCTs), we have screened tumors from 33 patients for loss of heterozygosity (LOH) using Southern blot analysis with 39 polymorphic markers covering 21 chromosome arms. Losses in more than 2 tumors and occurring at a frequency of > 10% were found on chromosome arms 5q, 11p, 11q, 13q, and 16p, the highest being on chromosome arm 5q (19%). It is suggested that tumor suppressor genes on 5q among others may be involved in testicular tumorigenesis and that LOH in this region requires further investigation. No losses were found on 12q and 17p despite the fact that the most common cytogenetic abnormality in TGCTs is an i(12p) and that the TP53 gene on 17p is the most frequently mutated gene in human cancers. The level of allelic imbalance varied considerably from one chromosome region to another (0-80%) and did not generally reflect the pattern of LOH. It tended to be high in overrepresented regions of the genome, 1q, 7p, and 12p. The tumor from one patient had a seminomatous component and a less differentiated component. We provide evidence for a common origin of both components and show that it is likely that this tumor has progressed from the seminoma to the less differentiated histology.
- Published
- 1995
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.